RALEIGH, N.C. - A North Carolina federal jury on May 14 found that Aredia or Zometa caused a plaintiff to develop osteonecrosis of the jaw (ONJ) and that manufacturer Novartis Pharmaceuticals Corp. failed to adequately warn of the risk, but the panel also found that an unreasonable failure to adequately warn was not the proximate cause of the ONJ, resulting in a defense verdict (Jimmy Earp v. Novartis Pharmaceuticals Corporation, No. 5:11-680, E.D. N.C., W. Div.).